IgA is necessary and sufficient to protect against norovirus infection 2258197
The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)
DOI: 10.1093/jimmun/vkag141.555 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Arya Ökten und 21 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Human norovirus (HNV) causes up to 700 million infections and 200,000 deaths each year, primarily affecting young children in low-resource settings. Despite this significant public health and economic impact, no licensed vaccines or anti-viral therapies exist for HNV. Several vaccine candidates are currently in advanced clinical trials, including virus-like particle (VLP), adenoviral (Ad5), and mRNA lipid nanoparticle (LNP) based vaccines. While these candidates show promise, none have demonstrated complete or long-term protection. The mechanisms underlying protective immunity to HNV remain poorly defined, posing a major barrier to rational vaccine design. Technical limitations make it challenging to directly interrogate mechanisms of HNV immunity, as there are no scalable cell culture, reverse genetics, or small animal models. Murine norovirus (MNV) is a genetically tractable model for HNV that shares many fundamental properties including minimal intestinal pathology, rare epithelial cell tropism, and fecal-oral transmission.
Methods
We used a panel of genetically and pharmacologically modified mice to investigate the correlates and cellular determinants of protection to MNV infection.
Results
T cell—dependent IgA is necessary to control MNV replication in the small intestine, whereas CD8+ T cells are dispensable. IgA plasma cells mediate protection from re-infection and dimeric IgA, but not monomeric, is sufficient to confer complete protection against MNV infection. In contrast, despite generating a robust systemic IgG response, systemic vaccination with the viral capsid protein (VP1) fails to protect mice, mirroring the recent failure of a systemic VLP vaccine in infants.
Conclusion
Our work shows that mucosal IgA is central to controlling norovirus infection in a murine model and provides important insights for rational vaccine design and HNV immunotherapeutics. Funding Source n/a Topic Categories Viral Immunology (VIR)
Zitieren
APA
Ökten, A., Filler, R., Fang, Z., McWilliams, B., Muscat-Rivera, J., Kung, J., Mari, I., Gomes, O., Mankowski, M., Skelly, A., Williams, A., Eisenbarth, S., Chen, S., Baldridge, M., Lee, S., Nice, T., Wobus, C., Smith, T., Weissman, D., …, & Wilen, C. (2026). IgA is necessary and sufficient to protect against norovirus infection 2258197. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.555
Vancouver
Ökten A, Filler R, Fang Z, McWilliams B, Muscat-Rivera J, Kung J, et al. IgA is necessary and sufficient to protect against norovirus infection 2258197. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.555
BibTeX
@article{kten2026,
author = {Ökten, Arya and Filler, Renata and Fang, Zhenhao and McWilliams, Brieyanna and Muscat-Rivera, Jenna and Kung, Justin and Mari, Ilze and Gomes, Olivi and Mankowski, Madeleine and Skelly, Ashwin and Williams, Adam and Eisenbarth, Stephanie and Chen, Sidi and Baldridge, Megan and Lee, Sanghyun and Nice, Timothy and Wobus, Christiane and Smith, Thomas and Weissman, Drew and Krieder, Edward and Craft, Joseph and Wilen, Craig},
title = {IgA is necessary and sufficient to protect against norovirus infection 2258197},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {Supplement_1},
doi = {10.1093/jimmun/vkag141.555}
}
EUVIMED